Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YL-7606
- Development stage
- Preclinical
- Lead developer
- Ionova Life Science
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
YL-7606 is an early-stage, orally bioavailable small molecule modulator of interleukin-17 (IL-17), specifically targeting IL-17A, under development by Ionova Life Science for the treatment of autoimmune and inflammatory diseases. By inhibiting the IL-17 signaling pathway, YL-7606 aims to suppress the downstream production of pro-inflammatory cytokines and chemokines, thereby reducing chronic inflammation and tissue damage associated with autoimmune disorders. The drug is currently in the discovery or IND-enabling preclinical stage.
02
Targets
IL-17A (Interleukin-17A)
Beyond the preview
Go deeper on YL-7606.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YL-7606.